Department of Psychiatry

Penn Behavioral Health

HVTN 110

About the Study

This is a phase 1 clinical trial to evaluate the safety and immune responses to an Adenovirus type-4 HIV vaccine regimen taken by mouth in combination with an AIDSVAX® B/E booster injection in healthy, HIV-uninfected adult participants. Up to 60 healthy, HIV negative volunteers, at low risk for HIV infection, aged 18 to 49 years will be enrolled at 12 sites in the United States. The study is a randomized, controlled, and double-blinded, meaning both research participants and staff will not know if the participant is receiving active vaccinations or placebos. The sexual partners of research participants will also be enrolled and monitored in this study.

Protocol Title

HVTN 110 A phase 1 clinical trial to evaluate the safety and immunogenicity of orally-administered replication-competent Adenovirus type-4 HIV vaccine regimens in combination with an AIDSVAX® B/E boost in healthy, HIV-uninfected adult participants

Principal Investigator

Ian Frank, MD
3535 Market St., 4th floor, Ste 4000
215-662-7419

Co-Investigators

David S. Metzger, PhD
3535 Market St., 4th floor, Ste 4000
215-746-7346

Debora Dunbar, MSN, CRNP
3535 Market St., 4th floor, Ste 4000
215-746-3713


Back to Top